Replimune Group, Inc.
Replimune Group, Inc. (REPL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
repl · pe ratio · data through Mar 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Replimune Group, Inc. (REPL) measures how much investors pay for each dollar of the company's trailing earnings. REPL's current PE ratio of N/A is calculated by dividing its stock price of $8.79 by its TTM earnings per share of -$3.42.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-03-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Replimune Group, Inc.You REPL | $726M | N/A | — | -$3.42 |
 Arvinas, Inc. ARVN | $469M | N/A | — | -$1.24 |
 Astria Therapeutics, Inc. ATXS | $718M | N/A | — | -$1.68 |
 ArriVent BioPharma, Inc. Common Stock AVBP | $1.4B | N/A | — | -$4.32 |
 Ginkgo Bioworks Holdings, Inc. DNA | $530M | N/A | — | -$5.64 |
 Iovance Biotherapeutics, Inc. IOVA | $1.4B | N/A | — | -$1.09 |
 MBX Biosciences, Inc. Common Stock MBX | $957M | N/A | — | -$2.38 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-03-31Latest FY2025 | — | $-3.07 | — | |
2024-03-31 FY2024 | — | $-3.24 | — | |
2023-03-31 FY2023 | — | $-2.99 | — | |
2022-03-31 FY2022 | — | $-2.26 | — | |
2021-03-31 FY2021 | — | $-1.75 | — | |
2020-03-31 FY2020 | — | $-1.54 | — | |
2019-03-31 FY2019 | — | $-1.33 | — | |
2018-03-31 FY2018 | — | $-0.64 | — | |
2017-03-31 FY2017 | — | $-0.36 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Replimune Group, Inc. (REPL) measures how much investors pay for each dollar of the company's trailing earnings. REPL's current PE ratio of N/A is calculated by dividing its stock price of $8.79 by its TTM earnings per share of -$3.42.
Frequently asked questions
REPL pe ratio · 6 questionsREPL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $8.79 and TTM EPS of -$3.42. Data sourced from Financial Modeling Prep via REPL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Replimune Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08